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.a.borg@goAbstract Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial
pathogen worldwide. Malta is one of the countries with the highest MRSA prevalence
in Europe, as identified from hospital blood cultures [1]. However, community preva-
lence ofMRSA has never previously been investigated. This study aimed at establishing
the prevalence of community MRSA nasal colonization in Maltese individuals and iden-
tifying the clonal characteristics of the detected isolates. Nasal swabs were collected
from 329 healthy individuals who were also asked to complete a brief questionnaire
about risk factors commonly associated with MRSA carriage and infection. The swabs
were transported and enriched in a nutrient broth supplemented with NaCl. The pres-
ence of MRSA was then determined by culturing on MRSA Select chromogenic agar and
then confirming by several assays, including catalase, coagulase and PBP2a agglutina-
tion tests. The isolates were assayed for antibiotic susceptibilities and typed bymicro-
array analysis to determine the clonal characteristics of each strain. The prevalence of
MRSA nasal colonization in the healthy Maltese population was found to be 8.81% (95%
confidence interval [CI], 5.75–11.87%), much higher than that found in other studies
carried out in several countries. No statistical association was found between MRSA
carriage and demographics or risk factors; however, this was hindered by the small
sample size. Almost all the isolates were fusidic-acid resistant. The majority were
found to belong to a local endemic clone (CC5) which seems to be replacing the pre-
viously prevalent European clone UK-EMRSA-15 in the country. A new clone (CC50-
MRSA-V) was also characterized. The presence of such a significant community reser-
voir of MRSA increases the burdens already faced by the local healthcare system to
control the MRSA epidemic. Colonization of MRSA in otherwise healthy individuals
may represent a risk for endogenous infection and transmission to hospitalized3 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd.
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166 J. Scerri et al.patients after admission to a healthcare facility, leading to longer hospital stays and,
consequently, increased healthcare costs.
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reserved.1. Introduction
Methicillin-resistant S. aureus (MRSA) is a major
nosocomial pathogen worldwide [2]. Its acquisition
of multiple antibiotic resistance mechanisms has
led to increasingly challenging infections [3]. Mul-
ti-resistant strains, only sensitive to glycopeptide
antibiotics, have been increasingly reported from
hospitals in several countries [4].
In the past, MRSA was mainly associated with
hospital settings. Risk factors for infection and col-
onization included recent or prolonged hospitaliza-
tion, nursing home admission, recent antimicrobial
therapy, chronic disease and contact with a colo-
nized individual [5]. Reports of MRSA outbreaks
among individuals without any healthcare-associ-
ated risk factors [6,7] have led to an increased
awareness of community-associated MRSA (CA-
MRSA). This ‘‘changing epidemiology’’ of MRSA
has several important clinical implications, since
increasing prevalence will increase antibiotic con-
sumption leading to greater risk of multidrug-resis-
tant MRSA within the community [8].
Apart from the absence of healthcare-associated
risk factors, CA-MRSA can often be distinguished
from healthcare-associated strains by different
microbiological, epidemiological and molecular
characteristics. Unlike healthcare-associated MRSA
(HA-MRSA), which is often associated with blood-
stream, respiratory tract and urinary infections,
CA-MRSA is more implicated in skin and soft tissue
infections, tends to be more prevalent in younger
patients and also generally shows a greater suscepti-
bility to non-b-lactam antibiotics [9]. CA-MRSA is of-
ten characterized by the presence of an SCC mec
type IV or V allele in the mec element [10,11] and
genes coding for specific endotoxins, especially
the Panton–Valentine leukocidin (PVL) associated
with an increased risk for skin and soft tissue infec-
tions [9,12]. All these factors indicate that new
MRSA strains can arise de novo from the community.
Although the United States Centers for Disease Con-
trol and Prevention (CDC) has established a set of
guidelines to distinguish CA-MRSA from HA-MRSA,
these are mostly based on the absence of health-
care-associated risk factors in the individual rather
than microbiological or molecular criteria [13].
HA-MRSA has been documented to be a major
challenge to theMaltese healthcare. Malta currentlyhas one of the highest proportions of MRSA in Europe
[1]. However, no other studies on the prevalence of
MRSA within the general community have been car-
ried out. This epidemiological study thus aimed to
determine the prevalence of MRSA nasal carriage
in the general population and to find out any rela-
tionship between colonization and published risk
factors.
2. Materials and methods
The study, which took place between August 2010
and March 2011, was approved by the University
of Malta Research Ethics Committee. 329 volun-
teers were recruited by random sampling as they
attended eight primary healthcare centers around
Malta. These recruits were not actual patients,
but their accompanying adult relatives or friends,
all of whom were asked to participate in the study.
Individuals who had been hospitalized within the
previous twelve months were excluded from the
study according to the established CDC guidelines
[13]. Upon accepting to take part in the study,
the volunteers were admitted to a private room
where a consent form with all the relevant details
was signed. A questionnaire was also administered,
aimed at determining whether the respondent had
any of the healthcare and/or community-associ-
ated risk factors for MRSA colonization reported
in previous studies.
Swabbing of both nostrils was carried out by a sin-
gle investigator (J.S.) using a sterile cotton swab
moistened in deionized sterile water. A standard
technique of swabbing both anterior nares was em-
ployed using the same swab and rubbing it against
the interior skin of the nose up to a depth of about
2.5 cm while gently rotating the swab for five times
to sample the entire area. The swab was immedi-
ately snapped into a 5 ml bijoux bottle in an enrich-
ment medium containing 4 ml of sterile nutrient
broth enriched with 2.5% sodium chloride and incu-
bated overnight. Each sample was then cultured on
MRSA Select chromogenic agar (Bio-Rad Laborato-
ries, Marnes-la-Coquette, France). Presumptive
MRSA strains, which grew as pink colonies on the
chromogenic medium, were confirmed by Gram
stain, catalase, slide coagulase by the ProlexTM Staph
Latex kit (Pro-Lab Diagnostics, Toronto, Canada),
and PBP 2 0 testing using the MastalexTM MRSA kit
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crobial susceptibility testing was also carried out
using the VITEK 2 system (bioMe´rieux, Marcy-l
Etoile, France), by AST-P580 Gram positive
susceptibility cards. Antibiotics tested included a
cefoxitin screen (used to confirm the presence of
MRSA and detect low level methicillin resistance),
benzylpenicillin, oxacillin, fusidic acid and mupiro-
cin, clindamycin and inducible clindamycin resis-
tance, tetracycline, as well as aminoglycosides
(gentamicin, tobramycin), quinolones (levofloxa-
cin, moxifloxacin), and glycopeptides (teicoplanin,
vancomycin).
Microarray-based characterization was carried
out on all the isolated and confirmed strains at
the Dresden University of Technology (refer to
[14] and [15] for detailed description of the tech-
nique). The simultaneous detection of several
molecular targets allowed the assignation of the
isolates to clonal complexes, as well as genotype-
based assessment of antibiotic resistance and viru-
lence factors. Antibiotic resistance genes included
those for penicillinase (blaZ), mecA defining meth-
icillin-resistance, and genes encoding resistance to
aminoglycosides, chloramphenicol, fusidic acid,
lincosamides, macrolides, tetracyclines, trimetho-
prim and vancomycin. Virulence factors included
various enterotoxins, toxic shock syndrome toxin
(tst1), exfoliative toxins and various haemolysins
and leukocidins, including Panton-Valentine leuko-
cidin. Probes allowing the identification of differ-
ent SCCmec types were also included.
Pearsons chi-square test (SPSS Statistics for
Windows, Version 17.0, Chicago: SPSS Inc.) was
used to determine whether there was any statisti-
cally significant correlation between the nasal car-
riage of MRSA and the demographics and risk
factors addressed in the questionnaire. A p-value
of 0.05 or less was taken to determine if differ-
ences were statistically significant.
The z-ratio for the significance of the difference
between two independent proportions (http://
www.mccallum-layton.co.uk/stats/ZTestTwo-
TailSampleValues.aspx) was also used to test
whether prevalent clones varied significantly in
terms of age group and risk factors at the 95% CI.
3. Results
The prevalence of MRSA nasal carriage in the Mal-
tese general population was 8.81% (95% CI, 5.75–
11.87%). Prevalence was higher in females (9.5%)
than in males (7.6%) as well as in lower age groups;
however, these differences were both not statisti-
cally significant (Table 1).No statistically significant association was found
between MRSA carriage and each community- or
healthcare-related risk factors using the chi-square
test (data not shown). In order to obtain some
more statistical strength owing to the small sample
size, risk factors were grouped according to cate-
gory; however, again no statistically significant
association was found (Table 2).
The antibiotic resistance patterns and the geno-
typic characteristics of the MRSA clones as deter-
mined by Vitek 2TM and microarray analysis,
respectively, are summarized in Table 3. All the
isolates were found to be resistant to at least one
non-b-lactam antibiotic. Resistance to fusidic acid
and streptogramins was the most prominent; all
strains but one were resistant to one, or the other,
or both. Resistance to other antibiotics included
levofloxacin and moxifloxacin (5 isolates, later con-
firmed to be UK-EMRSA-15), erythromycin and clin-
damycin (1 isolate), and tetracycline (1 isolate).
Upon microarray-based typing, the majority of
the strains (72.4%, 21 isolates) were assigned to
the clonal complex (CC) 5, termed the ‘‘Maltese
clone’’ because it appears to be, so far, endemic
to Malta [25]. This clone harbored the SCCmec IV
element. All isolates belonging to this clone carried
the putative fusidic acid resistance element,
Q6GD50 (fusC), and were genotypically resistant
only to fosfomycin and bleomycin. Furthermore,
all carried the gene for enterotoxin A (sea) and
the egc enterotoxin locus, and all but two also car-
ried genes for enterotoxins C (sec) and L (sel) and
toxic shock syndrome toxin (tst1). One of the two
isolates negative for sec, sel and tst1 was also neg-
ative for the beta-lactamase resistance genes blaZ,
blaI and blaR.
Five isolates (17.2%) belonged to ST22-MRSA-IV
(UK-EMRSA-15 or Barnim Epidemic MRSA Strain).
All of these isolates carried enterotoxins C and L.
Only one isolate carried a gene for macrolide/lin-
cosamide resistance (ermC), as well as Q6GD50
(fusC); no additional antibiotic resistance genes
were found in the other strains.
A single isolate belonged to the CC80-MRSA-IV
European CA-MRSA clone. While this strain is nor-
mally described as PVL-positive, however, the ac-
tual isolate resulted as PVL-negative on the
microarray. The isolate was positive for neomycin,
streptothricin, fusidic acid and tetracycline resis-
tance genes (aphA3, sat, far1 and tetK, respec-
tively), and exfoliative toxin D (etd); this
confirmed results of antibiotic susceptibility testing
(Table 3).
One isolate belonged to the ST6-MRSA-IV strain.
This is a rare strain which is usually found in
Table 2 Organization of risk factors in the questionnaire and results for chi–square test for association between MRSA
carriage and different risk factor categories. For the association between carriage and having any risk factor, the result of
the Fishers exact test is shown in brackets as one of the cells had an expected count of less than 5.
Risk Factors Categories MRSA carriage X2 value D.F. p-value
Positive Negative
Gym membership
Attendance at a day
care center
Sharing of personal items
Having a community
associated risk factor
Yes 13 (11.3%) 102 (88.7%) 1.364 1 0.243
No 16 (7.5%) 198 (92.5%)
Healthcare workers
Elderly relatives living in
nursing homes
Chronic relatives making
frequent hospital visits
Having relatives with
healthcare contacts
Yes 16 (10.5%) 137 (89.5%) 0.960 1 0.327
No 13 (7.4%) 163 (92.6%)
Chronic disease
History of skin infection
with boils/abscesses
Chronic skin disease
Nasal disease
Having a medical history
associated with MRSA
Yes 12 (7.1%) 158 (92.9%) 1.349 1 0.245
No 17 (10.7%) 142 (89.3%)
Antibiotic consumption
Surgery
Proximity to hospitalized
patients
Exposure to risk factors
in past year
Yes 20 (7.6%) 242 (92.4%) 2.233 1 0.135
No 9 (13.4%) 58 (86.6%)
All of the above Having any risk factor Yes 26 (8.3%) 288 (91.7%) 2.446 1 0.118 (0.136)
No 3 (20.0%) 12 (80.0%)
Table 1 Results for chi–square test for association between MRSA carriage and different demographics.
Demographics MRSA carriage Degrees of freedom p-value
Positive Negative
Gender Male 9 (7.6%) 109 (92.4%) 1 0.570
Female 20 (9.5%) 191 (90.5%)
Age Group 16–40 11 (14.7%) 64 (85.3%) 3 0.177
41–55 6 (8.0%) 69 (92.0%)
56–65 8 (8.3%) 88 (91.7%)
> 65 4 (4.8%) 79 (95.2%)
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MRSA-51). It carried the gene for resistance to
erythromycin and clindamycin (ermC), which con-
firmed phenotypic resistance to these antibiotics
(Table 3), as well as enterotoxin A.
Finally, a single isolate of a CC50-MRSA-V clone
was also characterized, which has never been de-
scribed as yet. This clone had a SCCmec V element,
andwas positive for Q6GD50 (fusC) indicating fusidic
acid resistance. MLST showed it to be a double locus
variant of ST50, with the profile 16-16-12-2-39-13-2.
It carried the egc enterotoxin gene cluster but was
negative for the toxic shock syndrome toxin gene
and other enterotoxin genes, as well as other antibi-
otic resistance gene loci. It did not carry PVL genes.
When MRSA carriers were grouped according to
strain type, no significant difference was observedbetween genders. The Maltese clone was predomi-
nant in the younger age groups (16–40 years;
Fig. 1) and in individuals with more than three risk
factors, while the other clones were more preva-
lent in older individuals (>56 years) and in those
with two risk factors for carriage. The z-ratio for
the significance of the difference between two
independent proportions showed a statistically sig-
nificant difference in the proportion of coloniza-
tion with the Maltese clone between the age
groups of 16–40 and >56 years.
4. Discussion
The prevalence of MRSA nasal carriage found in this
study is much higher than that reported in similar
studies from other locations, including Birmingham,
Table 3 Results of antibiotic resistance results obtained by the VITEK 2 system and strain characterization by microarray. mecA is the methicillin resistance gene; blaZ, blaI,
blaR are aˆ-lactamase resistance genes; fosB is a resistance gene for phosphomycin and bleomycin; Q6GD50 is a putative gene for fusidic acid resistance; ermC is an
erythromycin and clindamycin resistance gene; sat is a streptothricin resistance gene; far1 is a fusidic acid resistance gene; tetK is a tetracycline resistance gene.
MLSB = inducible clindamycin resistance; PVL = Panton–Valentine leukocidin; tsst-1 = toxic shock syndrome toxin 1; agr = accessory gene regulator; EDIN-B = epidermal cell
differentiation inhibitor B.
Strain Type No. of isolates
(% of total; n = 29)
VITEK 2 Microarray
Antibiotic Resistance Antibiotic Resistance
genes
PVL TSST-1 Entero-
toxins
Remarks
CC5-MRSA-IV (Maltese Clone);
agr group II
16 (55.2%) Oxacillin, Fusidic Acid,
Streptogramins
mecA, blaZ, blaI, blaR,
fosB, Q6GD50
Neg Pos A, C, L,
egc-cluster
1 (3.4%) Fusidic Acid, Streptogramins mecA, fosB, Q6GD50 Neg Neg A, egc-cluster
2 (6.8%) Fusidic Acid, Streptogramins mecA, blaZ, blaI, blaR,
fosB, Q6GD50
Neg Pos A, C, L,
egc-cluster
1 (3.4%) N/A mecA, blaZ, blaI, blaR,
fosB, Q6GD50
Neg Pos A, C, L,
egc-cluster
1 (3.4%) N/A mecA, blaZ, blaI, blaR,
fosB, Q6GD50
Neg Neg A, ecg-cluster
CC22-MRSA-IV (Barnim/
UK-EMRSA-15); agr group I
1 (3.4%) Oxacillin, Levofloxacin,
Moxifloxacin,
Fusidic Acid, Streptogramins,
Vancomycin-intermediate
mecA, blaZ, blaI, blaR,
Q6GD50, ermC
Neg Neg C, L,
egc-cluster
1 (3.4%) Oxacillin, Levofloxacin,
Moxifloxacin, Streptogramins
mecA, blaZ, blaI, blaR, Neg Neg C, L,
egc-cluster
1 (3.4%) Oxacillin, Levofloxacin,
Moxifloxacin, Streptogramins
mecA, blaZ, blaI, blaR, Neg Neg B, C, L,
egc-cluster
2 (6.8%) Oxacillin, Levofloxacin,
Moxifloxacin-intermediate,
Streptogramins
mecA, blaZ, blaI, blaR, Neg Neg B, C, L,
egc-cluster
ST6-MRSA-IV (WA-MRSA-51);
agr group I
1 (3.4%) Oxacillin, Erythromycin,
Clindamycin, MLSB inducible
mecA, blaZ, blaI, blaR,
ermC; sat, fosB
Neg Neg A
CC80-MRSA-IV; agr group III 1 (3.4%) Oxacillin, Tetracycline,
Fusidic Acid,
Streptogramins
mecA, blaZ, blaI, blaR,
aphA, sat, far1, tetK
Neg Neg Neg Other toxins:
exfoliative toxin D,
EDIN-B
CC50 (New Strain); agr group IV 1 (3.4%) Oxacillin, Fusidic Acid,
Streptogramins
mecA, blaZ, blaI, blaR,
Q6GD50
Neg Neg ecg-cluster
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Figure 1 Distribution of the different MRSA clones across age groups. The z-ratio calculation showed a statistically
significant difference in colonization with the Maltese clone between the smallest and largest age groups.
170 J. Scerri et al.the United Kingdom (1.5%) [16], Greece (0.94%)
[17], the United States (1.5%) [18], and Taiwan
(3.5%) [19]. This discrepancy could be owing to
several reasons. First of all, mentioned studies
predominantly employed direct inoculation of the
nasal swabs onto nutrient agar with horse blood
serum [16], oxacillin resistance screening agar
(ORSA) [17], or mannitol salt agar (MSA) [18,19].
Meanwhile, the sensitivity of this technique was
increased by incubation of the swabs in an enrich-
ment broth before inoculation onto chromogenic
medium [20], and this could have contributed at a
certain degree to an increased prevalence. Sec-
ondly, although ‘‘healthy’’ individuals were sam-
pled, they were nevertheless accompanying
relatives to primary healthcare centers; these rela-
tives could be regular attendees to the healthcare
centers and could thus have been themselves colo-
nized and transmitted the MRSA to the participants.
No significant association was found between
MRSA colonization and gender or age (p > 0.05).
This contrasts with other studies reporting a corre-
lation with ages of 60 years or more [18,21] and
gender [18,22]. Older individuals are more likely
to suffer from chronic illnesses and to have
frequent hospital contact, and would thus be
expected to be more at risk for colonization.
However, in this study, MRSA prevalence was
greater in younger ages and would support a truly
community-acquired etiology [9].
The majority of carriers (26/29, 89.7%) had at
least one risk factor for MRSA carriage; 25 individ-
uals (86.2%) had at least one healthcare-related
risk factor, namely relatives with healthcare con-
tacts, risk factors related to medical history and/
or healthcare-associated risk factor exposure with-
in the previous year. This was consistent with the
conclusion arrived at by Salgado et al. [5] that
many MRSA carriers in the community have one or
more healthcare-associated risk factors and thatmore adequate criteria for distinguishing between
CA- and HA-MRSA should be set-up. Most studies
have been carried out in populations attending
hospital outpatient centers and other healthcare
settings [22,23]; this study, although itself con-
ducted in a healthcare setting, was based on par-
ticipants who were not themselves patients and
who, consequently, were supposed to be less at
risk for MRSA carriage.
Several outbreaks of community-acquired MRSA
have been reported in specific settings, such as
athletic centers, and community-associated risk
factors have been associated with these outbreaks,
including sharing of towels [24]. Out of the 32 iso-
lates found in this study, only one came from an
individual who had been exposed to a community-
associated risk factor only, namely the sharing of
personal items, such as towels or razors, with other
individuals in the household. The others also had
healthcare-related risk factors. Furthermore, no
community-associated risk factors were linked with
MRSA carriage in our subjects. Therefore, these
isolates are better termed community-associated
rather than community-acquired, since their acqui-
sition could not be traced to a particular commu-
nity origin.
The rate of fusidic acid resistance in the isolated
MRSA strains was rather remarkable. In fact, 82.8%
of the strains (24/29, including two strains which
were not tested by VITEK 2, but which carried
the genes for resistance) were found to be resis-
tant. Fusidic acid-resistant MRSA is not common
in other parts of Europe. In the study by Karapsias
et al. [17], only two out of nine isolates (22.2%)
were fusidic acid-resistant. The increased carriage
of the fusidic acid resistance gene may be related
to a higher selective pressure, resulting from the
widespread use of this antibiotic in the country.
In fact, there is evidence of abuse of topical formu-
lations of fusidic acid in Malta [25]. Apart from
Prevalence of CA-MRSA in Malta 171fusidic acid and streptogramins, the majority of
strains were susceptible to other non-b-lactam
antibiotics. This correlates well with the view that
community-associated strains generally show a
greater susceptibility to non-b-lactam antibiotics
and are less likely than healthcare-associated
strains to be multidrug-resistant [9]. A single UK-
EMRSA-15 strain resulted as vancomycin-intermedi-
ate upon antibiotic susceptibility testing; this was
confirmed with Etest (MIC = 4 lg/ml), however,
the strain did not result in having any resistance
genes by microarray analysis. Such a finding was
also reported in a case of an S. aureus bloodstream
infection in Greece where the strain was also tei-
coplanin-resistant [26].
The majority of strains isolated belonged to the
endemic Maltese clone, a CC5-MRSA-IV variant.
This clone has already been described in a previous
Maltese study carried out on hospital strains, and
likewise carried the putative fusidic acid resistance
element, Q6GD50 (fusC), usually corresponding to
phenotypic resistance to fusidic acid [25] and pre-
vious work indicated a possible linkage to SCCmec
IV, or the presence of a composite SCC element
[15]. This study also described the presence of
the enterotoxin A gene (sea) and the egc entero-
toxin locus in all isolates, and sec, sel and tst1 in
nine out of ten isolates, which correlates well with
the findings as described in the results section and
also in Table 3. Fortunately, the strains isolated in
this study were susceptible to most antibiotics
tested.
The Maltese clone seems to be replacing UK EMR-
SA-15, the dominant strain across Western Europe
and previously the predominant clone in Maltese
hospital isolates [25]. The Malta clone was more
prevalent in younger individuals with no history of
hospitalization (Fig. 1), suggesting community
acquisition [8]. It is possible that this clone emerged
from the community and has disseminated to the
hospital; in fact, data from tertiary care suggest
that the Maltese clone has become predominant
even in this setting (personal communication).
A strain belonging to a new clone (CC50-V) was
also encountered. The presence of the novel
SCCmec V element and the absence of antibiotic
resistance genes on characterization of this strain
indicated community acquisition [11]; however,
toxic shock syndrome toxin gene and many other
enterotoxin genes were also absent. Unfortu-
nately, no travel history or other data which might
have been useful in determining the source of such
a strain was present.
Microarray typing confirmed all the isolates but
one to be of SCCmec type IV, which is associated
with, but not exclusive to, community strains. Thisfinding was rather consistent with the small degree
of non-b-lactam antibiotic resistance found in the
majority of the isolates, since SCCmec IV strains of-
ten lack several antibiotic resistance genes [10].
The same applies to SCCmec V found in CC50 [11].
No strain was found to carry the Panton-Valen-
tine leukocidin toxin, including the single isolate
belonging to the CC80 clone, which is usually
PVL-positive. Such a strain has been reported only
once in the Maltese literature, where it was iso-
lated from a hospital employee with no recorded
patient contact or travel history in continental Eur-
ope [25]. Once more, no travel history was avail-
able for this case.
This study faced several limitations. Like all
cross-sectional prevalence studies, it provided a
snapshot of the prevalence of MRSA nasal coloniza-
tion only at a given time period. Consequently,
intermittently colonized individuals might not have
been detected at the time. Risk factor analysis de-
pended on volunteer recall at the time of question-
ing and thus could not be fully accurate. Most
importantly, the sample size was relatively small,
even for a country of less than half a million inhab-
itants, resulting in a wide confidence interval. The
sample size did not allow the accurate determina-
tion of any association between MRSA carriage and
reported risk factors. The site where this study was
conducted constituted yet another limitation,
since primary health centers are still healthcare
settings, and although healthy volunteers who
had not been recently admitted to hospital were
selected, their relatives who were attending the
clinics could have been colonized themselves
through frequent visits to the clinics.5. Conclusions
Even with these limitations, the prevalence of
MRSA carriage in the Maltese community seems to
be very high, especially when compared with that
found in other countries. The presence of such a
significant community reservoir of MRSA increases
the burdens already faced by the local healthcare
system to control the MRSA epidemic. The pres-
ence of MRSA strains in up to 10% of admissions in-
creases the risk for cross transmission to
hospitalized patients and poses a major challenge
to control initiatives. Secondly, the local endemic
MRSA clone seems to be rather established in the
community and has replaced UK-EMRSA-15 as the
prevailing clone. Finally, the absence of PVL-posi-
tive strains is encouraging, considering the prob-
lems associated with community skin and soft
tissue infections caused by these strains.
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